LTWS Long-Term Wealth Stocks Long-term equity research
Premium Indian equities research

Long-Term Wealth Stocks

Premium long-term stock research focused on quality Indian businesses with strong wealth-creation potential.

Join Premium Past Successes
20+ Years Investing experience in Indian mid and small caps
₹4999 One-year premium access
5-6 Ideas High-quality companies shared annually

Annual premium offer

Members receive 5-6 high-conviction company ideas every year, along with detailed premium reports and a clean members-only library.

  • Deep-dive PDF stock reports
  • Members-only premium research library
  • Long-term wealth creation focus
  • Questions and comments directly through the platform
Premium access ₹4999 Valid for one full year
About the advisor

Built for patient investors

Backed by 20 years of investing experience in Indian mid-cap and small-cap companies, this service is built for serious investors who prefer patient compounding over noisy short-term calls.

This website is designed for a serious, premium member experience: clean dashboards, easy report access, and a simple annual subscription model.

What members receive

One premium annual plan

Members receive 5-6 high-conviction company ideas every year, along with detailed premium reports and a clean members-only library.

Annual premium access | 5-6 carefully selected companies | In-depth research reports | Direct questions to the advisor

Past Successes

A few exceptional winners can create life-changing wealth

My investing journey has shown me that meaningful wealth is often created by a handful of outstanding businesses rather than constant activity.

Transport Corporation of India

Transport Corporation of India — long holding led to 30x compounding

Transport Corporation of India has been one of my most powerful long-term investing experiences. Over a holding period of about 12 years, the investment compounded nearly 30 times. It is a clear example of how patient ownership in the right business can create truly life-changing wealth over time. This journey strengthened my conviction that a portfolio does not need many winners — just a few outstanding long-term compounders can make all the difference.

Held for 12 years 30x over 12 years
Neuland Laboratories

Neuland Laboratories — conviction rewarded over 4 years

Neuland Laboratories was another example of how focused research and disciplined holding can create exceptional returns. Over a period of roughly 4 years, the investment delivered around 8x returns. This was a strong reminder that wealth is often created not by frequent action, but by staying invested in quality businesses through time. Even a small number of such winners can meaningfully transform long-term portfolio outcomes.

Held for 4 years 8x over 4 years
Laurus Labs

Laurus Labs — patient holding created 10x wealth

Laurus Labs was one of the investments that reinforced my belief in patient long-term investing. I held the company for around 6 years, and that patience translated into nearly 10x wealth creation. Experiences like this have taught me that when the right business is identified early and given enough time, the compounding can be extraordinary. A few such winners can have a life-changing impact on overall portfolio wealth.

Held for 6 years 10x over 6 years

Past performance examples are shared for illustration and educational purposes only, and should not be interpreted as a promise of future returns.

Simple pricing

One plan. One year. One focused experience.

There is no monthly plan. Serious investors can subscribe for one year and get access to all premium reports during the subscription period.

  • Annual premium charge: ₹4999
  • Designed for around 200 premium members
  • Secure member login with premium access control
  • Clean premium library for stock reports

How it works

  1. Register with your name, email, phone number, city and comments.
  2. Log in to your dashboard and request premium activation.
  3. After payment confirmation, your premium access is activated.
  4. Read premium PDF reports in a clean members-only experience.
Create Account
Members-only research

Serious research, with the full stock idea reserved for members

The focus is on carefully selected long-term businesses where the downside is respected as much as the upside. Every idea is approached with emphasis on margin of safety, quality of management, strength of cash flows and sound business fundamentals, with the objective of compounding wealth while minimizing the risk of permanent capital loss.

Premium report

A mispriced pharma turnaround hiding behind one troubled product line

This is a business where headline weakness may be obscuring a far better underlying franchise. A weak commodity segment is dragging down reported performance, but the stronger core business is already showing healthier margins, better market positioning, and a clearer path to value creation. We think the next phase could look very different from the last few years.

Uploaded 04 Apr 2026
Premium report

A Scalable Wealth Franchise Built for India’s Next Decade

This report covers a high-quality financial services business that benefits from rising retail investing, recurring SIP flows, strong brand trust, and an asset-light, cash-generating model. It operates in a sector with long runway, high profitability, and expanding participation from Indian households as savings steadily shift toward financial assets.

Uploaded 04 Apr 2026
Premium report

A profitable pharma manufacturer with a powerful next phase of growth

This report covers a quietly strengthening healthcare business that combines steady execution, rising scale, and a promising expansion opportunity. With improving financial performance, deep customer relationships, and long-term industry tailwinds, it offers the kind of setup investors often look for before broader market recognition.

Uploaded 04 Apr 2026
Unlock Full Research
Questions from investors

Start a conversation

Prospective members and existing users can reach you here with questions, comments or membership requests.

Important disclaimer